Oramed Pharmaceuticals Inc. (ORMP) intrinsic value & 10-year financials
Oramed Pharmaceuticals Inc. (ORMP) has a Graham intrinsic value of $49.82 per share. At $4.07 on Oct 17, 2026, the stock trades 92% below that value. Over the last 10 fiscal years revenue grew 13.5% a year to $2.0M, with an average return on invested capital of -37.2%.
- Graham intrinsic value
- $49.82
- Share price (Oct 17, 2026)
- $4.07
- Price vs Graham value
- 92% below
- Market cap
- $172.6M
- Revenue (FY2025)
- $2.0M
- Revenue growth (10-yr CAGR)
- 13.5%
- ROIC (10-yr avg)
- -37.2%
- Free cash flow (FY2025)
- -$9.2M
ORMP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.0M | $64.0M | $1.50 | -$9.2M | -754.4% | -10.4% |
| FY2024 | — | -$19.1M | -$0.48 | -$8.4M | — | -8.6% |
| FY2023 | $1.3M | $5.5M | $0.14 | -$10.5M | -1176.8% | 3.5% |
| FY2022 | $2.7M | -$36.6M | $0.94 | -$28.4M | -1502.0% | -53.8% |
| FY2021 | $2.7M | -$23.0M | — | -$21.6M | -896.2% | -87.5% |
| FY2020 | $2.7M | -$11.5M | — | -$12.5M | -433.8% | -54.8% |
| FY2019 | $2.7M | -$14.4M | — | -$13.0M | -541.3% | -42.8% |
| FY2018 | $2.4M | -$12.7M | — | -$14.7M | -552.3% | -31.9% |
| FY2017 | $2.5M | -$10.5M | — | -$5.8M | -438.6% | -47.4% |
| FY2016 | $641.0K | -$11.0M | — | $4.6M | -1561.6% | -38.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ORAMED PHARMACEUTICALS INC. is a consistent compounder, expanding top-line revenue at 13.5% annually over the past decade.
ORAMED PHARMACEUTICALS INC. has historically struggled to out-earn its cost of capital, averaging just -37.2% ROIC.
ORAMED PHARMACEUTICALS INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ORAMED PHARMACEUTICALS INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $49.82 per share.